Navigating the transition from research to clinical-scale cell therapy manufacture

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Navigating the transition from research to clinical-scale cell therapy manufacture

The journey from concept to commercialization for cell therapy candidates is fraught with complex challenges, including escalating costs in process development, difficulties in scaling academic research to clinical applications, and navigating a complex regulatory landscape.

In this webinar, cell therapy leaders from Stanford School of Medicine, BioLabs, and Thermo Fisher Scientific will delve into how they have addressed key development hurdles. With a focus on delivering practical, high-impact outcomes, the speakers will share their experiences in overcoming cost and scalability barriers, and leveraging innovative technologies to optimize cell therapy process workflows and enhance efficiency.

Attend this webinar to learn about:

Overcoming cost barriers in process development
Navigating the transition from academic research to clinical scale
Harnessing modular process technologies to enhance efficiency
Understanding how incremental process improvements play a crucial role in advancing cell therapy

Steven Feldman

Site Head & Scientific Director of the Laboratory for Cell & Gene Medicine at Stanford University School of Medicine

Dr Feldman directs process development and manufacturing for the Stanford Center for Cancer Cell Therapy, Stanford Center for Curative and Definitive Medicine, and all other users of the Stanford University Laboratory of Cell and Gene Medicine’s GMP facility, be they Stanford faculty or industry partners. Dr Feldman’s lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors.

Johannes Fruehauf

Founder & CEO at LabCentral

Dr Fruehauf (MD PhD) is a physician-scientist and life-science entrepreneur. He is the Founder and CEO of Biolabs and LabCentral, the national network for biotech incubators and the largest co-working spaces for life-science startup companies. Together, Biolabs/LabCentral have helped launch over 850 venture funded startup companies in the life sciences in 16 different cities, and have a presence in the US, Germany, France and Japan.

Mary Ann Santos

Global Senior Manager, Cell Gene and Advanced Therapies, Strategic Collaborations at Thermo Fisher Scientific

Mary Ann Santos is a Global Senior Manager at Thermo Fisher Scientific focused on strategic collaborations for cell, gene and advanced therapies. She has over 27 years of experience in the biotechnology industry with expertise in Cell Biology and Life Sciences. This includes working with biotechnology, bioindustrial, and biopharmaceutical companies in addition to academic institutions in North America and across the globe.

in 24

Days